An Alexion Pharmaceuticals Inc. decision to cut ties with Moderna Therapeutics Inc., Blueprint Medicines Corp. and Arbutus Biopharma Corp. led an eventful day of biopharma earnings reports, shaped by better-than-expected results at the rare disease specialist.